Molecular pathology of gallbladder cancer

Molecular Surgical Pathology

Volumn 9781461449003, Issue , 2013, Pages 65-81

  Roa, Juan Carlos ^a   Adsay, N Volkan ^b  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949178548     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4900-3_4     Document Type: Chapter

References (66)

1. Aldridge MC, Bismuth H.Gallbladder cancer: the polypcancer sequence.Br J Surg.1990;77:363-4.
2. Bertran E, Heise K, Andia M, et al.Gallbladder cancer: incidence and survival in a high-risk area of Chile.Int J Cancer.2010;127:2446-54.
3. Buch S, Schafmayer C, Volzke H, et al.A genome-wide association scan identi fi es the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease.Nat Genet.2007;39:995-9.
4. Chang XZ, Yu J, Zhang XH, et al.Enhanced expression of trophinin promotes invasive and metastatic potential of human gallbladder cancer cells.J Cancer Res Clin Oncol.2009;135:581-90.
5. Chijiiwa K, Kimura H, Tanaka M, et al.Malignant potential of the gallbladder in patients with anomalous pancreaticobiliary ductal junction.The difference in risk between patients with and without choledochal cyst.Int Surg.1995;80:61-4.
6. Dixon E, Vollmer Jr CM, Sahajpal A, et al.An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center.Ann Surg.2005;241: 385-94.
7. Dutta U, Garg PK, Kumar R, et al.Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder.Am J Gastroenterol.2000;95:784-7.
8. Fox JG, Dewhirst FE, Shen Z, et al.Hepatic Helicobacter species identi fi ed in bile and gallbladder tissue from Chileans with chronic cholecystitis.Gastroenterology.1998;114:755-63.
9. Garcia P, Manterola C, Araya JC, et al.Promoter methylation pro fi le in preneoplastic and neoplastic gallbladder lesions.Mol Carcinog.2009;48:79-89.
10. Ghosh M, Kamma H, Kawamoto T, et al.MUC 1 core protein as a marker of gallbladder malignancy.Eur J Surg Oncol.2005;31:891-6.
11. Giatromanolaki A, Sivridis E, Simopoulos C, et al.Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas.J Surg Oncol.2006;94:242-7.
12. Hart J, Modan B, Shani M.Cholelithiasis in the aetiology of gallbladder neoplasms.Lancet.1971;1:1151-3.
13. Hsing AW, Gao YT, Rashid A, et al.Gallstones and the risk of biliary tract cancer: a population-based study in China.Br J Cancer.2007;97:1577-82.
14. Itoi T, Watanabe H, Ajioka Y, et al.APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis.Pathol Int.1996;46:333-40.
15. Juvonen T, Savolainen MJ, Kairaluoma MI, et al.Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease.J Lipid Res.1995;36:804-12.
16. Kashiwagi H, Kijima H, Dowaki S, et al.MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis.Oncol Rep.2001;8:485-9.
17. Kaufman M, Mehrotra B, Limaye S, et al.EGFR expression in gallbladder carcinoma in North America.Int J Med Sci.2008;5:285-91.
18. Kawamoto T, Krishnamurthy S, Tarco E, et al.HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer.Gastrointest Cancer Res.2007;1:221-7.
19. Kim JH, Kim HN, Lee KT, et al.Gene expression pro fi les in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis.Tumour Biol.2008;29: 41-9.
20. Kornprat P, Rehak P, Lemmerer M, et al.Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma.Virchows Arch.2005;446:505-10.
21. Kozuka S, Tsubone N, Yasui A, et al.Relation of adenoma to carcinoma in the gallbladder.Cancer.1982;50: 2226-34.
22. Lammert F, Miquel JF.Gallstone disease: from genes to evidence-based therapy.J Hepatol.2008;48 Suppl 1:S124-35.
23. Lazcano-Ponce EC, Miquel JF, Muñoz N, et al.Epidemiology and molecular pathology of gallbladder cancer.CA Cancer J Clin.2001;51:349-64.
24. Legan M, Luzar B, Marolt VF, et al.Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.World J Gastroenterol.2006;12:3425-9.
25. Li Q, Yang Z.Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.J Exp Clin Cancer Res.2009;28:65.
26. Li SH, Li CF, Sung MT, et al.Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray.Mod Pathol.2007;20:497-507.
27. Luzar B, Poljak M, Cor A, et al.Expression of human telomerase catalytic protein in gallbladder carcinogenesis.J Clin Pathol.2005;58:820-5.
28. Ma HB, Hu HT, Di ZL, et al.Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma.World J Gastroenterol.2005;11:744-7.
29. Misra S, Chaturvedi A, Misra NC, et al.Carcinoma of the gallbladder.Lancet Oncol.2003;4:167-76.
30. Nakashima T, Kondoh S, Kitoh H, et al.Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis.Int J Mol Med.2003;11:33-9.
31. Nakazawa K, Dobashi Y, Suzuki S, et al.Ampli fi cation and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.J Pathol.2005;206:356-65.
32. Nemeth Z, Szasz AM, Tatrai P, et al.Claudin-1,-2,-3,-4,-7,-8, and-10 protein expression in biliary tract cancers.J Histochem Cytochem.2009;57:113-21.
33. Nomoto M, Izumi H, Ise T, et al.Structural basis for the regulation of UDP-N-acetyl-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells.Cancer Res.1999;59:6214-22.
34. Ooi A, Suzuki S, Nakazawa K, et al.Gene ampli fi cation of Myc and its coampli fi cation with ERBB2 and EGFR in gallbladder adenocarcinoma.Anticancer Res.2009;29:19-26.
35. Pai R, Soreghan B, Szabo IL, et al.Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy.Nat Med.2002;8:289-93.
36. Paigen BC, Carey MC.Gallstones.In: King RA, editor.Rotter JI.Motulsky AG (eds): Genetic basis of common diseases.Oxford University Press; 2002.p.298-335.
37. Patel S, Roa JC, Tapia O, et al.Hyalinizing cholecystitis and associated carcinomas.Am J Surg Pathol.2011;35:1104-13.
38. Randi G, Franceschi S, La Vecchia C, et al.Gallbladder cancer worldwide: geographical distribution and risk factors.Int J Cancer.2006;118:1591-602.
39. Roa I, Araya JC, Shiraishi T, et al.DNA content in gallbladder carcinoma: a fl ow cytometric study of 96 cases.Histopathology.1993;23:459-64.
40. Roa I, Araya JC, Villaseca M, et al.Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression.Gastroenterology.1996;111: 232-6.
41. Roa I, Araya JC, Villaseca M, et al.Gallbladder cancer in a high risk area: morphological features and spread patterns.Hepatogastroenterology.1999;46:1540-6.
42. Roa JC, Anabalon L, Araya J, et al.Promoter methylation pro fi le in gallbladder cancer.J Gastroenterol.2006;41:269-75.
43. Roa JC, Roa I, Correa P, et al.Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder.J Gastroenterol.2005;40:79-86.
44. Roa JC, Vo Q, Roa I, et al.Inactivation of CDKN2A gene (p16) in gallbladder carcinoma.Rev Med Chil.2004;132:1369-76.
45. Roa JC, Tapia O, Cakir A, et al.Squamous cell and adenosquamous carcinomas of the gallbladder.Mod Pathol.2011;24:1069-78.
46. Saetta A, Lazaris AC, Davaris PS, et al.Detection of ras oncogene point mutations and simultaneous proliferative fraction estimation in gallbladder cancer.Pathol Res Pract.1996;192:532-40
47. Sasatomi E, Tokunaga O, Miyazaki K, et al.Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic fi ndings.J Hepatobiliary Pancreat Surg.2000;7:556-67.
48. Shi YZ, Hui AM, Li X, et al.Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas.Clin Cancer Res.2000;6:4096-100.
49. Shibata T, Kokubu A, Gotoh M, et al.Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.Gastroenterology.2008;135:1358-68.
50. Srivastava A, Tulsyan S, Pandey SN, et al.Single nucleotide polymorphism in the ABCG8 transporter gene is associated with gallbladder cancer susceptibility.Liver Int.2009;29:831-7.
51. Strom BL, Soloway RD, Rios-Dalenz JL, et al.Risk factors for gallbladder cancer.An international collaborative case-control study.Cancer.1995;76: 1747-56.
52. Takahashi T, Shivapurkar N, Riquelme E, et al.Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis.Clin Cancer Res.2004;10:6126-33.
53. Tang M, Baez S, Pruyas M, et al.Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma.Clin Cancer Res.2004;10:1041-6.
54. Tian Y, Ding RY, Zhi YH, et al.Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity.World J Gastroenterol.2006;12: 415-9.
55. Wang JW, Peng SY, Li JT, et al.Identi fi cation of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1.Cancer Lett.2009;281:71-81.
56. Wistuba II, Albores-Saavedra J.Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma.J Hepatobiliary Pancreat Surg.1999;6:237-44.
57. Wistuba II, Ashfaq R, Maitra A, et al.Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.Am J Pathol.2002;160:2073-9.
58. Wistuba II, Miquel JF, Gazdar AF, et al.Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas.Hum Pathol.1999;30:21-5.
59. Wu XS, Akiyama Y, Igari T, et al.Expression of homeodomain protein CDX2 in gallbladder carcinomas.J Cancer Res Clin Oncol.2005;131:271-8.
60. Xu LN, Zou SQ, Wang JM, et al.Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.World J Gastroenterol.2005;11:3719-23.
61. Yamagiwa H, Tomiyama H.Intestinal metaplasia-dysplasia-carcinoma sequence of the gallbladder.Acta Pathol Jpn.1986;36:989-97.
62. Yamamoto S, Kitadai Y, Tsuchida A, et al.Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions.Eur J Cancer.2000;36:257-63.
63. Yokoyama N, Watanabe H, Ajioka Y, et al.Genetic alterations in gallbladder carcinoma: a review.Nippon Geka Gakkai Zasshi.1998;99:687-95.
64. Yue SQ, Yang YL, Zhou JS, et al.Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.World J Gastroenterol.2004;10:2750-2.
65. Zhang M, Pan JW, Ren TR, et al.Correlated expression of inducible nitric oxide synthase and P53, Bax in benign and malignant diseased gallbladder.Ann Anat.2003;185:549-54.
66. Zong H, Yin B, Chen J, et al.Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma.Tohoku J Exp Med.2009; 217:203-8.